Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals develops and sells medicines for rare diseases, including sleep disorders, epilepsy and cancer. It last closed at $240.71 on Nov 17, up 0.39% on the day. JAZZ last reported earnings on Mon, Nov 2, 2026. The average 12-month price target from 11 analysts is $312.64 (+29.9% from the last close), with a high of $337.00 and a low of $275.00. Analyst consensus is Strong Buy, based on the latest ratings from 11 firms (11 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in JAZZ, 50% of them bullish and 50% bearish. In the past 30 days there were 9 dark pool prints totaling $9.1M, the largest $2.9M.
Key Stats
Last 12 monthsNot reported for this period.
From JAZZ's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 11 analysts who set a price target on JAZZ in the past 90 days. The average target is $312.64, with a high of $337.00 and a low of $275.00, compared with the last close of $240.71.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 13 | Morgan Stanley | Target raised | Buy | $319 → $324 |
| Nov 12 | Piper Sandler | Target raised | Buy | $310 → $330 |
| Nov 3 | JP Morgan | Target raised | Buy | $300 → $310 |
| Nov 3 | Morgan Stanley | Target raised | Buy | $314 → $319 |
| Nov 3 | RBC Capital | Target raised | Buy | $296 → $305 |
Technical Analysis
The stock is 6% above its 20 day and 5% above its 50 day average. It is 8% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 60), near overbought. The nearest support is the swing low (Aug 14) at $240.63, and the nearest resistance the swing high (Jun 5) at $241.99.
| RSI (14) | 59.66 | Middle of its range | Neutral |
| MACD | 5.36 | Above its signal line | Bullish |
| Stochastic | 80.0 | Near the top of its range | Overbought |
| ADX (14) | 31.7 | Trending up | |
| Williams %R | -20.9 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 71.1 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +4.8% | Change over 10 sessions | Bullish |
| ATR (14) | $7.25 | Typical daily range, 3.0% of price |
| RSI (14) | 57.59 | Middle of its range | Neutral |
| MACD | 4.00 | Below its signal line | Bearish |
| Stochastic | 57.3 | Middle of its range | Neutral |
| ADX (14) | 33.6 | Trending up | |
| Williams %R | -40.1 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 12.4 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −2.1% | Change over 10 sessions | Bearish |
| ATR (14) | $14.00 | Typical daily range, 5.8% of price |
What happened before
See how JAZZ did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How JAZZ has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2007.
Whale Options Flow
90DNo whale options trades in JAZZ in the last 90 days.
Dark Pool
30DJAZZ Institutional Ownership
Full report →- ▲366 buying vs 278 selling
- ▲Held by funds +1.0 pts
- ▲Funds holding +22
- ●Superinvestors: 2 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 669 | 647 | +3.4% |
| In funds' top 10 | 11 | 14 | −21.4% |
| Held by funds | 101.4% | 100.4% | +1.0 pts |
| New / increased | 104 / 262 | 129 / 243 | −1.6% |
| Reduced / sold out | 203 / 75 | 184 / 57 | +15.4% |
| Put/call ratio | 0.11 | 1.07 | −90.1% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether JAZZ is in one of them and how their past JAZZ trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered JAZZ in an article yet. Here's the latest on the wider market.
JAZZ Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Bryan BedfordExecutive branch | Sell | $50K – $100K | Sep 10, 2025 | Dec 19, 2025 | 100 d |
| Dan GoldmanD · NY | Sell | $15K – $50K | Jul 12, 2023 | Aug 13, 2023 | 32 d |
| Ro KhannaD · CA | Sell | $1K – $15K | May 19, 2023 | Jun 12, 2023 | 24 d |
| Dan GoldmanD · NY | Buy | $15K – $50K | Mar 6, 2023 | Apr 17, 2023 | 42 d |
| Ro KhannaD · CA | Buy | $1K – $15K | Mar 14, 2023 | Apr 7, 2023 | 24 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals is a biopharmaceutical company based in Dublin, Ireland. It develops and sells medicines for rare diseases, many of which have few or no existing treatment options. Its products include treatments for narcolepsy and other sleep disorders, medicines for certain forms of epilepsy, and cancer therapies. Its medicines are used by patients and prescribed by physicians in countries around the world.
- Headquarters
- Dublin
- Founded
- 2003
- Website
- jazzpharma.com ↗









